• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virpax Pharmaceuticals

Virpax to pursue over-the-counter pathway for topical spray treatment for osteoarthritis pain

June 27, 2022 By Sean Whooley

Virpax

Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it will pursue a direct to over-the-counter (OTC) regular pathway for Epoladerm. Berwyn, Pennsylvania–based Virpax designed the Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. According to a news release, the company expects the direct to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: Virpax Pharmaceuticals

Virpax completes FDA-required preclinical studies for pain-treating topical spray

March 22, 2022 By Sean Whooley

Virpax

Virpax Pharmaceuticals (Nasdaq:VRPX) announced today that it completed all FDA-required preclinical studies for its Epoladerm product. Berwyn, Pennsylvania-based Virpax designed its Epoladerm investigational pre-filled topical spray analgesic product for the non-addictive management of chronic pain associated with osteoarthritis (OA) of the knee. Its completed investigational new drug application (IND)-enabling studies included dermal toxicity, sensitization, irritation, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: FDA, Virpax Pharmaceuticals

Virpax touts study results for intranasal spray for treating acute, chronic pain

February 10, 2022 By Sean Whooley

Virpax

Virpax Pharmaceuticals (NSDQ:VRPX) today announced promising results from preclinical studies for its Envelta intranasal spray. Berwyn, Pennsylvania-based Virpax designed Envelta (NES100), an endogenous enkephalin intranasal spray, for treating acute and chronic pain, including pain associated with cancer. According to a news release, findings from preclinical dose range-finding studies for Envelta complement previous positive preclinical toxicology […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Preclinical Trials Tagged With: Virpax Pharmaceuticals

Virpax reports positive non-human study results for topical spray film that treats chronic pain

December 8, 2021 By Sean Whooley

Virpax

Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. According to a news release, the company reported positive results following the completion of a toxicology and […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals Tagged With: Charles River Laboratories, Virpax Pharmaceuticals

Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering

September 14, 2021 By Sean Whooley

Virpax

Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Additionally, the company granted underwriters a 45-day option to purchase up […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Hydrogels, Nanoparticles, Pain Management Tagged With: Virpax Pharmaceuticals

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS